Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | 10% owner | November 24, 2025 | December 18, 2025 |
| Mitesco, Inc.tnty · Entity 8540 | Director | February 07, 2017 | March 15, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date November 24, 2025 · Filed December 18, 2025
Jointly reported with 10X Fund, L.P., 10X Capital Management, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,614,457 |
Last balance in matching sequence
After 2025-12-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-11-24 · Other · Disposed 24,000 · Balance 5,645,138 F1: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Row 2 · 2025-12-16 · Sale · Disposed 30,681 · Balance 5,614,457 F3: The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law.
F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3: The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Mitesco, Inc.
Report date February 07, 2017 · Filed March 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 100,000 |
| Restricted Common StockSEC Table I · non-derivative | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 200,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2016 Filed Sep 8, 2017 20:34 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 484,036 | $1.13 | $546,960.68 |
DisclosureSEC source: 0001493152-17-010371 · form-4a.xml · nonDerivative · entry 3 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 2,729,213 F1 · kind: Distributed as an in-kind distribution to four withdrawing limited partners in 10X Fund, LP., which was effective as of 9/30/16. Transaction price is the closing market price on 9/30/16, although the actual transfer of the shares occurred later. F2 · shares: This Form 4/A amends a Form 4 originally filed 10/24/16, which reported the distribution of 229,383 shares to a withdrawing limited partner on 9/30/16, to correct the amounts of the distribution. The share distributions reported herein also include the share distributions reported in a Form 4 filed 11/15/16, which erroneously reported the distribution of 9,663 and 17,096 shares to a withdrawing limited partner on 11/10/16. F3 · ownership.direct: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| September 30, 2016 Filed Sep 8, 2017 20:34 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 164,110 | $1.13 | $185,444.30 |
DisclosureSEC source: 0001493152-17-010371 · form-4a.xml · nonDerivative · entry 2 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 3,213,249 F1 · kind: Distributed as an in-kind distribution to four withdrawing limited partners in 10X Fund, LP., which was effective as of 9/30/16. Transaction price is the closing market price on 9/30/16, although the actual transfer of the shares occurred later. F2 · shares: This Form 4/A amends a Form 4 originally filed 10/24/16, which reported the distribution of 229,383 shares to a withdrawing limited partner on 9/30/16, to correct the amounts of the distribution. The share distributions reported herein also include the share distributions reported in a Form 4 filed 11/15/16, which erroneously reported the distribution of 9,663 and 17,096 shares to a withdrawing limited partner on 11/10/16. F3 · ownership.direct: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| September 30, 2016 Filed Sep 8, 2017 20:34 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 92,451 | $1.13 | $104,469.63 |
DisclosureSEC source: 0001493152-17-010371 · form-4a.xml · nonDerivative · entry 1 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 3,377,359 F1 · kind: Distributed as an in-kind distribution to four withdrawing limited partners in 10X Fund, LP., which was effective as of 9/30/16. Transaction price is the closing market price on 9/30/16, although the actual transfer of the shares occurred later. F2 · shares: This Form 4/A amends a Form 4 originally filed 10/24/16, which reported the distribution of 229,383 shares to a withdrawing limited partner on 9/30/16, to correct the amounts of the distribution. The share distributions reported herein also include the share distributions reported in a Form 4 filed 11/15/16, which erroneously reported the distribution of 9,663 and 17,096 shares to a withdrawing limited partner on 11/10/16. F3 · ownership.direct: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| September 29, 2016 Filed Oct 24, 2016 23:43 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseLock-Up Warrant · Derivative | 1 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-16-014230 · form4.xml · derivative · entry 12 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 5 Underlying: Common Stock · 93,750 shares Expires 2023-09-29 F6 · derivative.exercise_price: The exercise price of the Series B-3 Warrant and the Lock-Up Warrant is subject to a one-time downward adjustment based upon the subsequent agreement between the company and a lead investor in the event the company prices its private offering below certain thresholds. F7 · price: On September 22, 2016, the company and 10X Fund, LP entered into a Lock-Up Agreement, under which the Company agreed to issue 10X Fund, L.P. Lock-Up Warrants to purchase 500,000 shares of common stock, plus additional Lock-Up Warrants to purchase 0.08333 shares of common stock for every $1 invested by 10X Fund, LP in the Company's Series B-3 Convertible Preferred Stock offering, up to a maximum of 500,000 warrants. F3 · ownership.direct: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| September 29, 2016 Filed Oct 24, 2016 23:43 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseLock-Up Warrant · Derivative | 1 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-16-014230 · form4.xml · derivative · entry 11 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 4 Underlying: Common Stock · 187,500 shares Expires 2023-09-29 F6 · derivative.exercise_price: The exercise price of the Series B-3 Warrant and the Lock-Up Warrant is subject to a one-time downward adjustment based upon the subsequent agreement between the company and a lead investor in the event the company prices its private offering below certain thresholds. F8 · price: On September 29, 2016, 10X Fund, L.P. purchased (a) 1,125,000 shares of Series B-3 Convertible Preferred Stock, (b) one Series B-3 Warrant to purchase 564,854 shares of common stock at 3.00 per share, and (c) one Lock-Up Warrant to purchase 187,500 shares of common stock at $3.00 per share, for total consideration of $1,125,000. F3 · ownership.direct: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| September 29, 2016 Filed Oct 24, 2016 23:43 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseSeries B-3 Warrant · Derivative | 1 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-16-014230 · form4.xml · derivative · entry 10 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 2 Underlying: Common Stock · 564,854 shares Expires 2023-09-29 F6 · derivative.exercise_price: The exercise price of the Series B-3 Warrant and the Lock-Up Warrant is subject to a one-time downward adjustment based upon the subsequent agreement between the company and a lead investor in the event the company prices its private offering below certain thresholds. F8 · price: On September 29, 2016, 10X Fund, L.P. purchased (a) 1,125,000 shares of Series B-3 Convertible Preferred Stock, (b) one Series B-3 Warrant to purchase 564,854 shares of common stock at 3.00 per share, and (c) one Lock-Up Warrant to purchase 187,500 shares of common stock at $3.00 per share, for total consideration of $1,125,000. F3 · ownership.direct: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| September 29, 2016 Filed Oct 24, 2016 23:43 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseSeries B-3 Convertible Preferred Stock · Derivative | 1,125,000 | $1.00 Strike: $1.49 | $1,125,000.00 |
DisclosureSEC source: 0001493152-16-014230 · form4.xml · derivative · entry 9 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 1,500,000 Underlying: Common Stock · 753,138 shares Expires not disclosed F8 · price: On September 29, 2016, 10X Fund, L.P. purchased (a) 1,125,000 shares of Series B-3 Convertible Preferred Stock, (b) one Series B-3 Warrant to purchase 564,854 shares of common stock at 3.00 per share, and (c) one Lock-Up Warrant to purchase 187,500 shares of common stock at $3.00 per share, for total consideration of $1,125,000. F4 · derivative.exercise_date: Each share of Series B-3 Convertible Preferred Stock is convertible immediately into shares of Issuer's common stock at a conversion price equal to the market price of the common stock on the date of issuance of the Series B-3 Convertible Preferred Stock, plus $0.9375 per share. F4 · derivative.expiration_date: Each share of Series B-3 Convertible Preferred Stock is convertible immediately into shares of Issuer's common stock at a conversion price equal to the market price of the common stock on the date of issuance of the Series B-3 Convertible Preferred Stock, plus $0.9375 per share. F3 · ownership.direct: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| September 22, 2016 Filed Oct 24, 2016 23:43 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseLock-Up Warrant · Derivative | 2 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-16-014230 · form4.xml · derivative · entry 8 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 3 Underlying: Common Stock · 531,250 shares Expires 2023-09-22 F6 · derivative.exercise_price: The exercise price of the Series B-3 Warrant and the Lock-Up Warrant is subject to a one-time downward adjustment based upon the subsequent agreement between the company and a lead investor in the event the company prices its private offering below certain thresholds. F7 · price: On September 22, 2016, the company and 10X Fund, LP entered into a Lock-Up Agreement, under which the Company agreed to issue 10X Fund, L.P. Lock-Up Warrants to purchase 500,000 shares of common stock, plus additional Lock-Up Warrants to purchase 0.08333 shares of common stock for every $1 invested by 10X Fund, LP in the Company's Series B-3 Convertible Preferred Stock offering, up to a maximum of 500,000 warrants. F3 · ownership.direct: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| September 22, 2016 Filed Oct 24, 2016 23:43 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseLock-Up Warrant · Derivative | 1 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-16-014230 · form4.xml · derivative · entry 7 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 1 Underlying: Common Stock · 62,500 shares Expires 2023-09-22 F6 · derivative.exercise_price: The exercise price of the Series B-3 Warrant and the Lock-Up Warrant is subject to a one-time downward adjustment based upon the subsequent agreement between the company and a lead investor in the event the company prices its private offering below certain thresholds. F5 · price: On September 22, 2016, 10X Fund, L.P. purchased (a) 375,000 shares of Series B-3 Convertible Preferred Stock, (b) one Series B-3 Warrant to purchase 104,408 shares of common stock at 3.00 per share, and (c) one Lock-Up Warrant to purchase 62,500 shares of common stock at $3.00 per share, for total consideration of $375,000. F3 · ownership.direct: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| September 22, 2016 Filed Oct 24, 2016 23:43 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseSeries B-3 Warrant · Derivative | 1 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-16-014230 · form4.xml · derivative · entry 6 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 1 Underlying: Common Stock · 104,408 shares Expires 2023-09-22 F6 · derivative.exercise_price: The exercise price of the Series B-3 Warrant and the Lock-Up Warrant is subject to a one-time downward adjustment based upon the subsequent agreement between the company and a lead investor in the event the company prices its private offering below certain thresholds. F5 · price: On September 22, 2016, 10X Fund, L.P. purchased (a) 375,000 shares of Series B-3 Convertible Preferred Stock, (b) one Series B-3 Warrant to purchase 104,408 shares of common stock at 3.00 per share, and (c) one Lock-Up Warrant to purchase 62,500 shares of common stock at $3.00 per share, for total consideration of $375,000. F3 · ownership.direct: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| September 22, 2016 Filed Oct 24, 2016 23:43 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseSeries B-3 Convertible Preferred Stock · Derivative | 375,000 | $1.00 Strike: $2.69 | $375,000.00 |
DisclosureSEC source: 0001493152-16-014230 · form4.xml · derivative · entry 5 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 375,000 Underlying: Common Stock · 139,211 shares Expires not disclosed F5 · price: On September 22, 2016, 10X Fund, L.P. purchased (a) 375,000 shares of Series B-3 Convertible Preferred Stock, (b) one Series B-3 Warrant to purchase 104,408 shares of common stock at 3.00 per share, and (c) one Lock-Up Warrant to purchase 62,500 shares of common stock at $3.00 per share, for total consideration of $375,000. F4 · derivative.exercise_date: Each share of Series B-3 Convertible Preferred Stock is convertible immediately into shares of Issuer's common stock at a conversion price equal to the market price of the common stock on the date of issuance of the Series B-3 Convertible Preferred Stock, plus $0.9375 per share. F4 · derivative.expiration_date: Each share of Series B-3 Convertible Preferred Stock is convertible immediately into shares of Issuer's common stock at a conversion price equal to the market price of the common stock on the date of issuance of the Series B-3 Convertible Preferred Stock, plus $0.9375 per share. F3 · ownership.direct: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| June 30, 2016 Filed Oct 24, 2016 23:43 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 80,212 | $1.47 | $117,911.64 |
DisclosureSEC source: 0001493152-16-014230 · form4.xml · nonDerivative · entry 1 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 3,340,909 F1 · kind: Received as a dividend on shares of Series B-1 and B-2 Convertible Preferred Stock owned by 10X Fund, L.P. F3 · ownership.direct: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| June 30, 2016 Filed Jan 9, 2017 21:53 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 124,524 | $1.45 | $180,559.80 |
DisclosureSEC source: 0001493152-17-000290 · form4a.xml · nonDerivative · entry 1 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 3,385,221 F1 · kind: Common stock received in satisfaction of $180,000 of dividends due on Series B Convertible Preferred Stock owned by 10X Fund, L.P. pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. This Form 4/A amends the original filing to correct the number of share issued in payment of the dividend, and to correct the price per share at which the dividend was paid in common stock. F1 · price: Common stock received in satisfaction of $180,000 of dividends due on Series B Convertible Preferred Stock owned by 10X Fund, L.P. pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. This Form 4/A amends the original filing to correct the number of share issued in payment of the dividend, and to correct the price per share at which the dividend was paid in common stock. F3 · balance_after: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| April 20, 2016 Filed Nov 18, 2016 22:10 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 11,212 | $1.57 | $17,636.48 |
DisclosureSEC source: 0001493152-16-015280 · form4a.xml · nonDerivative · entry 2 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 3,260,697 F2 · price: Reflects weighted average price. Range of gross prices were between $1.55 and $1.62. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. This Form 4/A amends the original filing to show the net sales price after deduction of commissions charged by the selling broker. F3 · balance_after: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
| April 19, 2016 Filed Nov 18, 2016 22:10 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 33,100 | $1.68 | $55,614.62 |
DisclosureSEC source: 0001493152-16-015280 · form4a.xml · nonDerivative · entry 1 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 10X Fund, LP Disclosed balance after: 3,271,909 F1 · price: Reflects weighted average price. Range of gross prices were between $1.69 and $1.715. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. This Form 4/A amends the original filing to show the net sales price after deduction of commissions charged by the selling broker. F3 · balance_after: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.